Treatment of Nonalcoholic Steatohepatitis (NASH)

NASH is a major cause of cirrhosis of the liver that leads to end stage liver disease and cancer.Oral Tocotrienol rich fraction (TRF) supplementation induces stem cell population (oval cells) in liver and protects the progression of NASH.Currently ther…
  • NASH is a major cause of cirrhosis of the liver that leads to end stage liver disease and cancer.
  • Oral Tocotrienol rich fraction (TRF) supplementation induces stem cell population (oval cells) in liver and protects the progression of NASH.
  • Currently there are no approved medications approved to treat NASH.

Abstract:

Non-alcoholic fatty liver disease (NAFLD) refers to a group of conditions where there is accumulation of excess fat in the liver of people who drink little or no alcohol. Non-alcoholic steatohepatitis (NASH) represents the most extreme form of NAFLD and has become one of the leading indications for liver transplantation. NASH is a major cause of cirrhosis of the liver that leads to end stage liver disease and liver cancer. Despite intensive investigations, there are currently no approved therapies for treating NASH. The first line of treatment for NAFLD and NASH is weight loss, done through a combination of calorie reduction, exercise, and healthy eating. A novel treatment method has been found to prevent the progression of NASH and protect the liver from NASH induced liver injury. Oral Tocotrienol rich fraction (TRF) supplementation induces liver stem cells, bipotent oval cells, to protect from the progression of NASH. TRF supplementation in the murine model showed decreased lipid accumulation, steatosis, inflammation, and fibrosis in the liver. TRF supplementation induced oval cell production and conversion of the oval cells into hepatocytes to help regenerate and repair the liver.

Website:

https://iu.flintbox.com/technologies/47E6C620DBB047ED96DC8AA7C57C5223

Advantages:

Globally over 15 million people suffer from NAFLD and 20% of those develop NASH. Treatment with the novel tocotrienol rich fraction in mice has stopped the progression of NASH and induced the formation of hepatocytes to help repair the liver. A phase II human clinical trial is ongoing to support and further evaluate this findings with an expected end date of 2026. The broader Phase I clinical study helped to determine the concentrations of tocotrienols, provided evidence that oral administration of TRF is transmitted to vital organs, and laid the foundation for the Phase II study. No adverse effects of tocotrienol administration were reported.

Contact Information:

Name : Tyson Rugenstein

Email : trugenst@iu.edu

Phone : 317-278-1916